Government-Owned Inventions; Availability for Licensing, 2287-2288 [E7-626]

Download as PDF Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices For Further Information Contact: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Charles Land, Project Officer, National Cancer Institute, EPS , 6120 Executive Boulevard MSC 7238, Bethesda, Maryland 20852, or call non-toll free number 301–594–7165 or FAX your request, including your address to 301– 402–0207. Comments Due Date Comments regarding this information collection are best assured of having their full effect if received within 60 days of this publication. Dated: January 8, 2007. Rachelle Ragland-Greene, NCI Project Clearance Liaison, National Institutes of Health. [FR Doc. E7–625 Filed 1–17–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: pwalker on PROD1PC71 with NOTICES SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other Mental Disorders Description of Technology: Dopamine is a neurotransmitter that exerts important effects on locomotor activity, VerDate Aug<31>2005 17:52 Jan 17, 2007 Jkt 211001 motivation and reward, and cognition. The dopamine transporter (DAT) is expressed on the plasma membrane of dopamine synthesizing neurons, and is responsible for clearing dopamine released into the extra-cellular space, thereby regulating neurotransmission. The dopamine transporter plays a significant role in neurotoxicity and human diseases, such as Parkinson’s disease, drug abuse (especially cocaine addiction), Attention Deficit Disorder/ Attention Deficit Hyperactivity Disorder (ADD/ADHD), and a number of other CNS disorders. Therefore, the dopamine transporter is a strong target for research and the discovery of potential therapeutics for the treatment of these indications. This invention discloses novel benztropine analogs and methods of using these analogs for treatment of mental and conduct disorders such as cocaine abuse, narcolepsy, ADHD, obesity and nicotine abuse. The disclosed analogs are highly selective and potent inhibitors of DAT, but without an apparent cocaine-like behavioral profile. In addition to their use as a treatment for cocaine abuse, these compounds have also shown efficacy in animal models of ADHD and nicotine abuse, and have also been shown to reduce food intake in animals. They may also be useful medications for other indications where dopaminerelated behavior is compromised, such as alcohol addiction, tobacco addiction, and Parkinson’s disease. Applications: Drug leads for treatment of cocaine abuse, ADHD, nicotine abuse, obesity, and other dopamine-related disorders; Imaging probes for dopamine transporter binding sites. Development Status: Pre-clinical data are available. Inventors: Amy H. Newman, Mu-fa Zou, and Jonathan L. Katz (NIDA). Patent Status: U.S. Provisional Application No. 60/710,956 filed 24 Aug 2005 (HHS Reference No. E–234– 2005/0–US–01); PCT Application No. PCT/US2006/33103 filed 24 Aug 2006 (HHS Reference No. E–234–2005/1– PCT–01 and HHS Reference No. E–129– 2006/0). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Tara Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov. Collaborative Research Opportunity: The Medicinal Chemistry and Psychobiology Sections, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 2287 commercialize medications to treat cocaine abuse and addiction. Please contact John D. Hewes, Ph.D. at 301/ 435–3121 or hewesj@mail.nih.gov for more information. Protein Arginine N-methyltransferase 2 (PRMT–2), a Modulator of NFKB, E2F1, and STAT3 Activity Description of Technology: Proteinarginine methyltransferases (PRMTs) contain methyltransferase domains that modify chromatin and regulate cellular transcription through the posttranslational methylation of arginine residues on the guanidine group of target proteins. Members of this family have roles in RNA processing, transcriptional regulation, signal transduction, and DNA repair. Until recently, the functional significance of one member of this family, PRMT–2, was unknown. Researchers at NHLBI, led by Dr. Elizabeth Nabel, have elucidated the role of PRMT–2. They have found that PRMT–2 modulates the activity of NFKB, E2F1, and STAT3. PRMT–2 inhibits NFKB dependent transcription, and therefore PRMT–2 has a role in modulating inflammation and the immune response. Also, PRMT–2 proteins can repress E2F1 transcriptional activity and cause cell cycle arrest, and thus may be used to treat or prevent cancer. PRMT–2 also methylates STAT3, and inhibition or loss of PRMT–2 function causes mammals to lose weight, eat less and become more sensitive to insulin. The invention describes methods of modulating PRMT–2 activity or expression in cells. These methods can be used to inhibit the function of NF?B, E2F1 and STAT3 for treatment of a number of disorders, including inflammation, cancer, and diabetes. Applications: Target for treatment and study of a number of disorders, including: Diabetes, obesity and metabolic syndrome diseases; Inflammation and immune response-related disorders; Cancer. Inventors: Elizabeth Nabel (NHLBI), Hiroaki Iwasaki (NHLBI), Takanobu Yoshimoto (NHLBI), and Gary Nabel (NIAID). Patent Status: U.S. Provisional Application No. 60/466,751 filed 30 April 2003 (HHS Reference No. E–190– 2003/0–US–01); PCT Application No. PCT2004/013375 filed 30 April 2004, which published as WO 2004/098634 on 18 Nov 2004 (HHS Reference No. E– 190–2003/0–PCT–02); U.S. Application No. 11/263,657 filed 31 Oct 2005, which published as WO 2006/0239990 on 26 E:\FR\FM\18JAN1.SGM 18JAN1 2288 Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices Oct 2006 (HHS Reference No. E–190– 2003/0–US–04). Licensing Status: Available for exclusive or nonexclusive licensing. Licensing Contact: Tara Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov. Dated: January 9, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–626 Filed 1–17–07; 8:45 am] pwalker on PROD1PC71 with NOTICES VerDate Aug<31>2005 17:52 Jan 17, 2007 Jkt 211001 National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Meeting BILLING CODE 4140–01–P Methods for Assaying Hair Follicle Growth and Development Description of Technology: Methods of culturing functionally-intact hair follicles in a collagen matrix are useful for screening baldness treatments and the quantification and study of the effects of agents on hair follicle growth. This technology describes techniques for measuring cell proliferation or for measuring secretion of collagenolytic factors, incorporating a threedimensional hair follicle culture system. Collagenolytic activity is essential for downgrowth of hair follicles during anagen. One described method measures the effects of a growth factor or pharmaceutical compound on cell proliferation, utilizing the incorporation of tritiated thymidine into DNA of cultured hair follicles. Also described is a method to measure the effect of growth factors on the release of collagenolytic factors, utilizing tritiated collagen or a fluorescent marker. Applications: Assays for screening drugs or growth factors that may stimulate hair growth; Assays measuring the DNA synthesis and collagenasesecreting activity of hair follicles. Market: An estimated 40 million men and 20 million women suffer from hair loss; The market size for hair restoration procedures in the United States is approximately $800 million. Inventor: Stuart H. Yuspa (NCI). Publications: 1. G Rogers, N Martinet, P Steinert, P Wynn, D Roop, A Kilkenny, D Morgan, SH Yuspa. Cultivation of murine hair follicles as organoids in a collagen matrix. J Invest Dermatol. 1987 Oct;89(4):369–379. 2. W Weinberg, P Brown, WG StetlerStevenson, SH Yuspa, Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation. 1990 Dec;45(3):168–178. Patent Status: U.S. Patent No. 5,616,471 issued 01 Apr 1997 (HHS Reference No. E–213–1987/1–US–01). Licensing Status: Available for nonexclusive licensing. Licensing Contact: Tara Kirby, Ph.D.; 301/435–4426; tarak@mail.nih.gov. DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Initial Review Group, Subcommittee G—Education. Date: February 6–7, 2007. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Washington Court Hotel, 525 New Jersey Avenue, NW., Washington, DC 20001. Contact Person: Sonya Roberson, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8109, Bethesda, MD 20892, 301–594–1182, robersos@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: January 9, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–178 Filed 1–17–07; 8:45 am] BILLING CODE 4140–01–M PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed blow in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Advisory Council. Date: February 14, 2007. Open: 8 a.m. to 12 p.m. Agenda: Discussion of program policies and issues. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Closed: 1 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31, 31 Center Drive, Conference Room 6, Bethesda, MD 20892. Contact Person: Stephen Mockrin, PhD, Director, Division of Extramural Research Activities, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7100, Bethesda, MD 20892, (301) 435–0260, mockrins@nhlbi.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a E:\FR\FM\18JAN1.SGM 18JAN1

Agencies

[Federal Register Volume 72, Number 11 (Thursday, January 18, 2007)]
[Notices]
[Pages 2287-2288]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-626]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other 
Mental Disorders

    Description of Technology: Dopamine is a neurotransmitter that 
exerts important effects on locomotor activity, motivation and reward, 
and cognition. The dopamine transporter (DAT) is expressed on the 
plasma membrane of dopamine synthesizing neurons, and is responsible 
for clearing dopamine released into the extra-cellular space, thereby 
regulating neurotransmission. The dopamine transporter plays a 
significant role in neurotoxicity and human diseases, such as 
Parkinson's disease, drug abuse (especially cocaine addiction), 
Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder 
(ADD/ADHD), and a number of other CNS disorders. Therefore, the 
dopamine transporter is a strong target for research and the discovery 
of potential therapeutics for the treatment of these indications.
    This invention discloses novel benztropine analogs and methods of 
using these analogs for treatment of mental and conduct disorders such 
as cocaine abuse, narcolepsy, ADHD, obesity and nicotine abuse. The 
disclosed analogs are highly selective and potent inhibitors of DAT, 
but without an apparent cocaine-like behavioral profile. In addition to 
their use as a treatment for cocaine abuse, these compounds have also 
shown efficacy in animal models of ADHD and nicotine abuse, and have 
also been shown to reduce food intake in animals. They may also be 
useful medications for other indications where dopamine-related 
behavior is compromised, such as alcohol addiction, tobacco addiction, 
and Parkinson's disease.
    Applications: Drug leads for treatment of cocaine abuse, ADHD, 
nicotine abuse, obesity, and other dopamine-related disorders; Imaging 
probes for dopamine transporter binding sites.
    Development Status: Pre-clinical data are available.
    Inventors: Amy H. Newman, Mu-fa Zou, and Jonathan L. Katz (NIDA).
    Patent Status: U.S. Provisional Application No. 60/710,956 filed 24 
Aug 2005 (HHS Reference No. E-234-2005/0-US-01); PCT Application No. 
PCT/US2006/33103 filed 24 Aug 2006 (HHS Reference No. E-234-2005/1-PCT-
01 and HHS Reference No. E-129-2006/0).
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426; 
tarak@mail.nih.gov.
    Collaborative Research Opportunity: The Medicinal Chemistry and 
Psychobiology Sections, National Institute on Drug Abuse-Intramural 
Research Program, National Institutes of Health, is seeking statements 
of capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize medications to 
treat cocaine abuse and addiction. Please contact John D. Hewes, Ph.D. 
at 301/435-3121 or hewesj@mail.nih.gov for more information.

Protein Arginine N-methyltransferase 2 (PRMT-2), a Modulator of 
NF[Kappa]B, E2F1, and STAT3 Activity

    Description of Technology: Protein-arginine methyltransferases 
(PRMTs) contain methyltransferase domains that modify chromatin and 
regulate cellular transcription through the post-translational 
methylation of arginine residues on the guanidine group of target 
proteins. Members of this family have roles in RNA processing, 
transcriptional regulation, signal transduction, and DNA repair. Until 
recently, the functional significance of one member of this family, 
PRMT-2, was unknown.
    Researchers at NHLBI, led by Dr. Elizabeth Nabel, have elucidated 
the role of PRMT-2. They have found that PRMT-2 modulates the activity 
of NF[Kappa]B, E2F1, and STAT3. PRMT-2 inhibits NF[Kappa]B dependent 
transcription, and therefore PRMT-2 has a role in modulating 
inflammation and the immune response. Also, PRMT-2 proteins can repress 
E2F1 transcriptional activity and cause cell cycle arrest, and thus may 
be used to treat or prevent cancer. PRMT-2 also methylates STAT3, and 
inhibition or loss of PRMT-2 function causes mammals to lose weight, 
eat less and become more sensitive to insulin.
    The invention describes methods of modulating PRMT-2 activity or 
expression in cells. These methods can be used to inhibit the function 
of NF?B, E2F1 and STAT3 for treatment of a number of disorders, 
including inflammation, cancer, and diabetes.
    Applications: Target for treatment and study of a number of 
disorders, including:
    Diabetes, obesity and metabolic syndrome diseases; Inflammation and 
immune response-related disorders; Cancer.
    Inventors: Elizabeth Nabel (NHLBI), Hiroaki Iwasaki (NHLBI), 
Takanobu Yoshimoto (NHLBI), and Gary Nabel (NIAID).
    Patent Status: U.S. Provisional Application No. 60/466,751 filed 30 
April 2003 (HHS Reference No. E-190-2003/0-US-01); PCT Application No. 
PCT2004/013375 filed 30 April 2004, which published as WO 2004/098634 
on 18 Nov 2004 (HHS Reference No. E-190-2003/0-PCT-02); U.S. 
Application No. 11/263,657 filed 31 Oct 2005, which published as WO 
2006/0239990 on 26

[[Page 2288]]

Oct 2006 (HHS Reference No. E-190-2003/0-US-04).
    Licensing Status: Available for exclusive or nonexclusive 
licensing.
    Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426; 
tarak@mail.nih.gov.

Methods for Assaying Hair Follicle Growth and Development

    Description of Technology: Methods of culturing functionally-intact 
hair follicles in a collagen matrix are useful for screening baldness 
treatments and the quantification and study of the effects of agents on 
hair follicle growth. This technology describes techniques for 
measuring cell proliferation or for measuring secretion of 
collagenolytic factors, incorporating a three-dimensional hair follicle 
culture system. Collagenolytic activity is essential for downgrowth of 
hair follicles during anagen. One described method measures the effects 
of a growth factor or pharmaceutical compound on cell proliferation, 
utilizing the incorporation of tritiated thymidine into DNA of cultured 
hair follicles. Also described is a method to measure the effect of 
growth factors on the release of collagenolytic factors, utilizing 
tritiated collagen or a fluorescent marker.
    Applications: Assays for screening drugs or growth factors that may 
stimulate hair growth; Assays measuring the DNA synthesis and 
collagenase-secreting activity of hair follicles.
    Market: An estimated 40 million men and 20 million women suffer 
from hair loss; The market size for hair restoration procedures in the 
United States is approximately $800 million.
    Inventor: Stuart H. Yuspa (NCI).
    Publications:
    1. G Rogers, N Martinet, P Steinert, P Wynn, D Roop, A Kilkenny, D 
Morgan, SH Yuspa. Cultivation of murine hair follicles as organoids in 
a collagen matrix. J Invest Dermatol. 1987 Oct;89(4):369-379.
    2. W Weinberg, P Brown, WG Stetler-Stevenson, SH Yuspa, Growth 
factors specifically alter hair follicle cell proliferation and 
collagenolytic activity alone or in combination. Differentiation. 1990 
Dec;45(3):168-178.
    Patent Status: U.S. Patent No. 5,616,471 issued 01 Apr 1997 (HHS 
Reference No. E-213-1987/1-US-01).
    Licensing Status: Available for nonexclusive licensing.
    Licensing Contact: Tara Kirby, Ph.D.; 301/435-4426; 
tarak@mail.nih.gov.

    Dated: January 9, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-626 Filed 1-17-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.